This dynamic new report from Medtech Insight includes analyses of products, competitors, and opportunities in the U.S. market for osteoporosis diagnosis and treatment products. During the forecast period covered by this report, the U.S. market for osteoporosis management products is projected to grow to an estimated $6.4 billion by the year 2017. This market, as covered by the scope of this report, includes diagnostic products (including bone densitometry systems and bone remodeling biochemical marker tests) and current and emerging pharmaceutical treatments (including bisphosphonates, estrogen agonists/antagonists, estrogen and estrogen/progestin therapies, monoclonal antibody inhibitors, salmon calcitonin, and synthetic parathyroid hormone).
EXECUTIVE SUMMARY i. Osteoporosis Incidence and Prevalence ii. Osteoporosis Diagnosis and Management a. Bone Densitometry b. Biochemical Markers c. Pharmaceutical Treatments iii. Market Analysis a. Bone Densitometry Systems b. Biochemical Markers c. Pharmaceutical Treatments i. Estrogen/Hormone Therapy Drugs ii. Osteoporosis Drugs iv. Methodology Exhibit ES-1: 2012, Osteoporosis-Caused Fracture Incidence, by Site Exhibit ES-2: Osteoporosis Management Products, Combined Market Forecast, 2012-2017 Exhibit ES-3: Bone Densitometry Systems, Market Forecast, 2012-2017 Exhibit ES-4: Bone Remodeling Biochemical Marker Tests, Market Forecast, 2012-2017 Exhibit ES-5: Pharmaceutical Treatments for Osteoporosis, Market Forecast, 2012-2017 Exhibit ES-6: 2012, Pharmaceutical Treatments for Osteoporosis, Sales by Product Category 1. OVERVIEW OF OSTEOPOROSIS 1.1 Incidence, Prevalence, and Cost 1.2 Types of Osteoporosis 1.3 Risk Factors Exhibit 1-1: Osteoporotic Bone and Normal Bone Exhibit 1-2: 2012, Osteoporosis-Caused Fracture Incidence, by Site Exhibit 1-3: Osteoporosis or Low Bone Mass in Women Age 50 and Older, by Race and Ethnicity Exhibit 1-4: Types of Osteoporosis Exhibit 1-5: Leading Risk Factors for Osteoporosis 2. BONE DENSITOMETRY PRODUCTS MARKET 2.1 Bone Densitometry Overview 2.1.1 Dual-Energy X-Ray Absorptiometry 2.1.2 Single-Energy X-Ray Absorptiometry 2.1.3 Radiographic Absorptiometry 2.1.4 Quantitative Computed Tomography 2.1.5 Quantitative Ultrasound 2.1.6 Hospital-Based Densitometry Systems 2.1.7 Office-Based Densitometry Systems 2.1.8 Software-Based Densitometry Systems 2.2 Densitometry Products 2.2.1 BeamMed 2.2.2 CompuMed 2.2.3 CooperSurgical/The Cooper Companies 2.2.4 Furuno USA/Furuno Electric Company 2.2.5 GE Healthcare/General Electric Company 2.2.6 Hologic 2.2.7 Lone Oak Medical Technologies 2.2.8 Sectra 2.3 Reimbursement 2.4 Market Analysis 2.5 Competitive Analysis Exhibit 2-1: Comparison of Biochemical Markers and Bone Densitometry as Tools for Diagnosing and Monitoring Osteoporosis Exhibit 2-2: Imaging Technologies Used to Diagnose Osteoporosis Exhibit 2-3: 2013, Selected Bone Densitometry Systems Exhibit 2-4: The Sunlight MiniOmni Bone Sonometer Exhibit 2-5: The Norland Family of Dual-Energy X-Ray Absorptiometry Systems Exhibit 2-6: The Lunar iDXA Dual-Energy X-Ray Absorptiometry System Exhibit 2-7: The Discovery Dual-Energy X-Ray Absorptiometry System Exhibit 2-8: The OsteoGram Radiographic Absorptiometry System Exhibit 2-9: The CM-200 Quantitative Ultrasound Bone Densitometry System Exhibit 2-10: The Accudxa2 Dual-Energy X-Ray Absorptiometry System Exhibit 2-11: Hospital-Based Bone Densitometry Systems, Market Forecast, 2012-2017 Exhibit 2-12: Office-Based Bone Densitometry Systems, Market Forecast, 2012-2017 Exhibit 2-13: Total Bone Densitometry Systems, Market Forecast, 2012-2017 Exhibit 2-14: 2012, Bone Densitometry Systems Market, Share by Supplier 3. BONE REMODELING BIOCHEMICAL MARKER TESTS MARKET 3.1 Biochemical Markers Overview 3.1.1 Types of Bone Turnover Markers 3.1.2 Applications 3.2 Biochemical Marker Testing Products 3.2.1 Alere 3.2.2 Beckman Coulter 3.2.3 Roche Diagnostics/Roche 3.2.4 Immunodiagnostic Systems 3.2.5 Orion Diagnostica/Orion Group 3.2.6 Quidel 3.3 Reimbursement 3.4 Market Analysis 3.5 Competitive Analysis Exhibit 3-1: The Bone Remodeling Cycle Exhibit 3-2: Comparison of Selected Bone Remodeling Biochemical Marker Tests Exhibit 3-3: 2013, Selected Bone Remodeling Biochemical Marker Tests Exhibit 3-4: Bone Remodeling Biochemical Marker Tests, Market Forecast, 2012-2017 Exhibit 3-5: 2012, Bone Remodeling Biochemical Marker Tests Market, Share by Supplier 4. OSTEOPOROSIS PHARMACEUTICAL TREATMENTS MARKET 4.1 Clinical Overview 4.1.1 Antiresorptive Drugs 184.108.40.206 Bisphosphonates 220.127.116.11.1 Alendronate 18.104.22.168.2 Ibandronate 22.214.171.124.3 Risedronate 126.96.36.199.4 Zoledronate 188.8.131.52 Salmon Calcitonins 184.108.40.206.1 Novartis 220.127.116.11.2 Unigene Laboratories 18.104.22.168.3 Emerging Drugs 22.214.171.124 Estrogen/Hormone Therapy 126.96.36.199 Receptor Activator of Nuclear Factor KappaB Ligand Inhibitors 188.8.131.52 Estrogen Agonists/Antagonists 184.108.40.206.1 Emerging Drugs 220.127.116.11.1.1 Pfizer 18.104.22.168.1.2 EndoCeutics 22.214.171.124 Other Emerging Antiresorptives 126.96.36.199.1 Cathepsin K Inhibitors 188.8.131.52.2 Monoclonal Antibodies 184.108.40.206.2.1 Alethia Biotherapeutics 220.127.116.11.2.2 Novo Nordisk 4.1.2 Bone-Forming Drugs 18.104.22.168 Synthetic Parathyroid Hormone 22.214.171.124.1 Forteo 126.96.36.199.2 Pipeline Drugs 188.8.131.52.2.1 Radius Health 184.108.40.206 Other Emerging Anabolic Drugs 220.127.116.11.1 Serotonin Inhibitors 4.1.3 Bone Morphogenetic Proteins 4.1.4 Dual-Action Bone Agents 18.104.22.168 Strontium Ranelate 22.214.171.124 Strontium Malonate 4.1.5 Gene Therapy 4.2 Market Analysis 4.2.1 Estrogen/Hormone Therapy Drugs 4.2.2 Osteoporosis Drugs 126.96.36.199 Bone-Building Drugs 188.8.131.52 Bisphosphonates 184.108.40.206 Receptor Activator of Nuclear Factor KappaB Ligand Inhibitors 220.127.116.11 Salmon Calcitonin 4.3 Competitive Analysis Exhibit 4-1: 2013, Selected Pharmaceutical Treatments for Osteoporosis Exhibit 4-2: 2013, Selected Emerging Pharmaceutical Treatments for Osteoporosis Exhibit 4-3: Estrogen/Hormone Therapy and Osteoporosis Drugs, Market Forecast, 2012-2017 Exhibit 4-4: 2012, Estrogen/Hormone Therapy and Osteoporosis Drugs, Sales by Product Category Exhibit 4-5: United States Patent Status of Selected Estrogen/ Hormone Therapy Drugs Exhibit 4-6: United States Patent Status of Selected Osteoporosis Drugs Exhibit 4-7: 2012, Estrogen/Hormone Therapy and Osteoporosis Drugs Market, Share by Supplier 5. COMPANY PROFILES 5.1 Alere, Inc 5.2 The Cooper Companies, Inc 5.3 GE Healthcare/General Electric Company 5.4 Hologic, Inc 5.5 Eli Lilly and Company 5.6 Novartis AG 5.7 Pfizer, Inc 5.8 Roche Holding AG APPENDIX: COMPANY LISTING